thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
=== General === Although well developed and diversified, the local economy relies heavily on industrial sites, international groups, and subcontracted SMEs. The Le Havre economy is far from decision centres which are located mainly in Paris and major European economic cities. There is therefore a low representation of head offices in the city with the exception of some local economic successes such as the Sidel Group (now a subsidiary of Tetra Pak) – a distributor of interior furniture, and the ship-owner Delmas which was recently acquired by the CMA CGM.
== Isoforms == Like 95% of human genes, TP53 encodes multiple proteins, collectively known as the p53 isoforms. These vary in size from 3.5 to 43.7 kDa. Since their initial discovery in 2005, 12 human p53 isoforms have been identified: p53α, p53β, p53γ, ∆40p53α, ∆40p53β, ∆40p53γ, ∆133p53α, ∆133p53β, ∆133p53γ, ∆160p53α, ∆160p53β, and ∆160p53γ. Isoform expression is tissue-dependent, and p53α is never expressed alone. The isoforms differ by the inclusion or exclusion of specific domains. Some, such as Δ133p53β/γ and Δ160p53α/β/γ, lack the transactivation or proline-rich domains and are deficient in apoptosis induction, illustrating the functional diversity of TP53. Isoforms are generated through multiple mechanisms:
The Goths were expanding towards the Lower Danube from the 230s, forcing the native peoples to flee to the Roman Empire or to accept their suzerainty. The Goths' rule ended abruptly when the Huns invaded their territory in 376, causing new waves of migrations. The Huns forced the remnants of the local population into submission, but their empire collapsed in 454. The Gepids took possession of the former Dacia province. Place names that are of Slavic origin abound in Romania, indicating that a significant Slavic-speaking population lived in the territory. The first Slavic groups settled in Moldavia and Wallachia in the 6th century, in Transylvania around 600. The nomadic Avars defeated the Gepids and established a powerful empire around 570. The Bulgars, who also came from the European Pontic steppe, occupied the Lower Danube region in 680.
Gene splicing techniques are being looked at to try to repair a genome with the erroneous gene that causes HD, using tools such as CRISPR/Cas9. PTC Therapeutics is evaluating small molecules that induce poison exon inclusion in HTT transcript as a therapeutic strategy to lower HTT expression. In 2025, researchers at University College London reported preliminary results from AMT-130, a phase 1/2 uniQure huntingtin-lowering gene therapy clinical trial, that showed a 75% slowing of disease progression over three years; the full study data has not yet been released peer-reviewed nor published. AMT-130 is a gene therapy utilising adeno-associated virus serotype 5 (AAV5) vector carrying an artificial micro-RNA to silence the gene leading to a lowering of huntingtin protein expression. The therapy is delivered directly into the deep brain structures of the caudate nucleus and putamen via an MRI guided neurosurgical procedure.
Sources: en.wikipedia.org
Appropriate technology options in water treatment include both community-scale and household-scale point-of-use (POU) or self-supply designs. Such designs may employ solar water disinfection methods, using solar irradiation to inactivate harmful waterborne microorganisms directly, mainly by the UV-A component of the solar spectrum, or indirectly through the presence of an oxide photocatalyst, typically supported TiO2 in its anatase or rutile phases. Despite progress in SODIS technology, military surplus water treatment units like the ERDLator are still frequently used in developing countries. Newer military style Reverse Osmosis Water Purification Units (ROWPU) are portable, self-contained water treatment plants are becoming more available for public use. For waterborne disease reduction to last, water treatment programs that research and development groups start in developing countries must be sustainable by the citizens of those countries. This can ensure the efficiency of such programs after the departure of the research team, as monitoring is difficult because of the remoteness of many locations. Energy Consumption: Water treatment plants can be significant consumers of energy. In California, more than 4% of the state's electricity consumption goes towards transporting moderate quality water over long distances, treating that water to a high standard. In areas with high quality water sources which flow by gravity to the point of consumption, costs will be much lower. Much of the energy requirements are in pumping.
General Souleymane Kelefa Diallo – former Guinean army chief of staff Mohamed Béavogui (Loma/Fulani) – Prime Minister of Guinea Mohamed Bayo – soccer player Pablo Thiam – soccer player Yadaly Diaby – soccer player Abdourahmane Barry Boubacar Barry – German football player Sadou Diallo Ibrahima Barry and Abdoulaye Barry – Creators of one of the only indigenous writing scripts in Africa, the Adlam script for the Fula language.
Advanced characterization of bacterial organisms can be also performed, allowing to obtain the necessary depth and breadth of coverage for genetic characterization results. Gene calling can be performed in a variety of ways, including RAST or using NCBI services at the time of full genome submission. Results of multiple annotation tools can be compared for accuracy and completeness and, if necessary, merged using BEACON. For characterization of antibiotic resistance genes, the Resistance Gene Identifier from the Comprehensive Antibiotic Resistance Database (CARD) is commonly used. To characterize virulence factor genes, ShortBRED offers analyses with a customized database from the Virulence Factor Database.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.